Search

for
Search:

Glossary Kintor Pharmaceuticals

Kintor Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for hair loss and other dermatological conditions. It is particularly known for its research on the topical androgen receptor inhibitor, KX-826, which aims to treat androgenetic alopecia by targeting the underlying hormonal factors contributing to hair loss. The company's work is relevant to hair biology as it explores new mechanisms to combat hair thinning and promote regrowth, distinguishing itself through its commitment to addressing both male and female pattern baldness.

Related Terms

Community Join

5 / 202 results

community Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study

17 upvotes 1 year ago

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

community New Hair Loss Treatment from Kintor Just Hit the Market: KX-826!

36 upvotes 2 years ago

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

community Potentially Positive Pyrilutamide News Coming

6 upvotes 6 months ago

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

community Veradermics is now public with a billion dollar market cap.

53 upvotes 7 months ago

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

community Kintor stealing pictures from a hair transplant clinic to promote their failed product (KX826, Pyrilutamide)

in Product 314 upvotes 2 years ago

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

View more "kintor pharmaceuticals" in community →

Learn

2 / 801 results

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

learn Pyrilutamide

highly targeted anti-androgen that might have minimal systemic effects

View more "kintor pharmaceuticals" in learn →

Research

5 / 447 results

research Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation

August 2025 in “Aesthetic Plastic Surgery”

This review explores the mechanisms, current products, challenges, and innovative approaches related to cosmetics for hair loss prevention and growth promotion, emphasizing the need for multidisciplinary cooperation to enhance product development and market success.

research Trace elements content and hormonal profiles in women with androgenetic alopecia

18 citations , December 2010 in “Journal of Trace Elements in Medicine and Biology”

This study suggests that alterations in copper metabolism may play a key role in the development of androgenetic alopecia in women, presenting potential targets for treatment strategies.

research A Study to Evaluate the Efficacy of Baicapil Formulations in Treatment of Telogen Effluvium

October 2018 in “International journal of clinical & experimental dermatology”

In this pilot study, baicalin-containing serum significantly decreased hair loss and increased hair growth after two months in participants with telogen effluvium, as subjective and objective assessments showed statistically significant improvements in hair thickness and density.

research Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?

2 citations , July 2018 in “Risks”

This study suggests that investing in a longevity megafund can significantly reduce longevity risk for pension funds, as it aligns financial returns with longevity and lowers associated economic capital needs.

research Safety and Efficacy of Rice Bran Supercritical CO₂ Extract for Hair Growth in Androgenic Alopecia: A 16-Week Double-Blind Randomized Controlled Trial

7 citations , January 2015 in “Biological & Pharmaceutical Bulletin”

This study found that a 16-week dermal application of rice bran extract significantly increased hair density and diameter in male androgenic alopecia patients without causing adverse reactions.

View more "kintor pharmaceuticals" in research →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →